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Abstract
Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with
infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with
broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and
the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated
(HCAP) and ventilator-associated (VAP) pneumonia.
Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational
studies.
Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled
efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1
(I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including
MDR pathogens.
Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with
a good safety profile.
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Background
Pneumonia is one of the major threats and leading cause
of death due to infectious diseases worldwide, in both
adults and children [1]. Mortality for community-acquired
pneumonia (CAP) ranges from < 5% among outpatients
up to 30% in those admitted in an intensive care unit [2].
Hospital-acquired pneumonia is the second most com-
mon nosocomial infection and the first in terms of mortal-
ity [3]. One of the major drivers of the high impact of
pneumonia on patients’ morbidity and mortality is repre-
sented by infections with multi-drug resistant (MDR) bac-
teria and, among them, methicillin resistant
Staphylococcus aureus (MRSA) plays a relevant rule in
both CAP and HAP [4].
Over the past two decades, antimicrobial resistance
has become a tangible reality not only for patients with
hospital-acquired (HAP), ventilator-associated (VAP) or
healthcare-associated (HCAP) pneumonia but also for
those coming from the community [5]. It has been rec-
ognized as a clinical and public health threat, which
should be immediately addressed in order to avoid a dra-
matic back to a pre-antibiotic era. The clinical misman-
agement of the antibiotics and the misuse in agriculture
and in veterinary medicine are favoring the rapid in-
crease of the rate of antibiotic resistant bacterial strains
worldwide. The research and development activities of
the pharmaceutical companies in the bacterial field have
significantly decreased since the 1980s’ for several rea-
sons, including an increased prevalence of chronic dis-
eases, the complex design of the clinical trials requested
* Correspondence: stefano.aliberti@unimi.it
2Department of Pathophysiology and Transplantation, University of Milan,
Milan, Italy
3Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult
Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan,
Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sotgiu et al. Respiratory Research          (2018) 19:205 
https://doi.org/10.1186/s12931-018-0905-x
by regulatory agencies, and the increasing antibiotic re-
sistance rates.
One of the most promising antibiotics recently mar-
keted is ceftaroline fosamil, a fifth-generation cephalo-
sporin which proved a both in vitro and in vivo
broad-spectrum activity against gram-positive (including
methicillin susceptible and resistant S. aureus -MSSA
and MRSA) and –negative bacteria. Ceftaroline fosamil
showed clinical and bacteriological efficacy against bac-
terial pathogens responsible of CAP and skin infections
[6]. Furthermore, during the pre-marketing studies, it
showed a good safety and tolerability profile [7].
The aim of the present study was to perform a system-
atic review and meta-analysis to evaluate the efficacy
and the effectiveness of ceftaroline fosamil in patients
with any kind of pneumonia described in experimental
and observational studies, respectively.
Methods
Search strategy
9pt?>Experimental and observational studies aimed to
evaluate the efficacy/effectiveness of ceftaroline fosamil in
adult hospitalized patients and outpatients with a diagnosis
of pneumonia, including CAP, HAP, VAP, and HCAP, were
selected. The search was conducted in three electronic da-
tabases: PubMed, Scopus, and Cochrane Central Register
of Controlled Trials, without any time restrictions. Only
publications written in English language were selected. Sev-
eral key-words, combined using different strings according
to the electronic database protocols, were used: “Ceftaro-
line”, “Ceftaroline Fosamil”, and “Respiratory Infections”.
To increase the search sensitivity, the list of references of
the selected articles, as well as published systematic or nar-
rative reviews, were manually and carefully assessed to in-
clude manuscripts not cited in the search record lists.
Abstracts of the main pulmonology, infectious diseases, or
microbiology conferences were not searched based on the
poor information they could provide on the selection cri-
teria and on the main clinical and bacteriological findings.
Furthermore, non-peer-reviewed articles of the grey litera-
ture were not considered based on their poor clinical and
methodological reliability.
Article selection
Only articles clearly describing the primary objective of
this systematic review, i.e. efficacy/effectiveness of Cef-
taroline fosamil in patients with pneumonia (CAP, HAP,
VAP, and HCAP) were selected. At least one of the fol-
lowing efficacy/effectiveness-related outcomes were con-
sidered: 1) number of responders/number of subjects in
group at day 4 after initiating therapy; 2) cure rate at the
end of therapy (EOT); 3) cure rate at the test of cure (8–
15 days after the end of therapy, TOC); 4) 14-day clinical
success/cure (±1 day) from the diagnosis of pneumonia.
The assessment of the outcomes and, then, the suitabil-
ity of the article was carried out during the evaluation of
the abstract or the full-text article if the information was
not stated in the abstract. Studies were included if adult
(≥18 years of age) patients, recruited in the ceftaroline
fosamil or in the control arm, were at least 20.
The following exclusion criteria were adopted for the
searched records: 1) papers written in languages other
than English; 2) narrative or systematic reviews and
meta-analyses; 3) abstracts presented in national and
international conferences; 4) editorials, research letters,
commentaries, correspondences; 5) case-reports or –
series; 6) manuscripts focused only on efficacy/effective-
ness of ceftaroline fosamil in infections other than
respiratory.
Safety and tolerability profile of ceftaroline fosamil in-
cluded only the collection of the adverse events.
Records were independently assessed by two re-
searchers (LS and FT). They carefully evaluated titles
and contents of the abstracts. In case of potential inter-
esting articles, they retrieved and assessed the full-text.
Inconsistencies during the first and second phase were
solved by a third and senior reviewer (GS), who super-
vised the entire selection and review process.
Data extraction
Qualitative and quantitative data were extracted by the
same reviewers (LS and FT) who selected the articles.
Collection of the variables was decided during the prep-
aration of the study protocol, as well as the implementa-
tion of an ad-hoc standardized form in an Excel format
(Microsoft Office). Disparity during data collection was
solved by a third reviewer (GS) by consensus. However,
the final inter-rater agreement was approximately 100%.
A random cross-check was carried out for ~ 20% of the
selected citations.
The following variables were collected: response rate at
day 4, response rate EOT, response rate TOC, 14-day clin-
ical cure, publication year, epidemiological study design,
country/ies where the study was carried out, study period,
sample size (total, ceftaroline and control arm), age, gen-
der, ethnic origin, severity of pneumonia, including the
Pneumonia Severity Index (PSI) [2], lobar infiltration,
pleural effusion, parenchymal or airway disease, previous
episodes of pneumonia or bacteremia, previous exposure
to antibiotics, asthma, etiology (i.e., S. pneumoniae, MSSA
and MRSA), and adverse events. According to the Italian
law on epidemiological studies based on anonymous and
aggregated data, no ethical clearance was requested to the
ethical committees of Milan and Sassari, Italy.
Study quality assessment
The systematic review and meta-analysis was carried out
following the Preferred Reporting Items for Systematic
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Reviews and Meta-Analyses (PRISMA) [8]. No signifi-
cant inconsistencies and disparities were detected in the
selection and data extraction phases. The agreement be-
tween LS and FT was higher than 97% and incongru-
ences were solved by the intervention of GS.
Statistical analysis
A descriptive analysis of qualitative and quantitative
variables was performed using proportions and central
tendency/variability indicators (i.e., mean and standard
deviation, SD), respectively. A meta-analysis was con-
ducted for the efficacy/effectiveness-related outcomes.
Forest plots were adopted to show the characteristics
(i.e., between-study variability and sample size) of the
single outcomes in comparison with the pooled esti-
mates. Point and interval (95% confidence intervals,
CI) estimates were used for studies’ and pooled out-
comes. The inconsistency (I2) indicator was computed
to show the variability across studies and was statisti-
cally tested with the chi-squared test for heterogen-
eity. Fixed or random-effects models were
implemented according to the assumption that the
true effect is or is not the same in all studies, re-
spectively. Stratified analyses were conducted follow-
ing the type of pneumonia (i.e., CAP, HAP, VAP,
HCAP) or the etiology (i.e., S. pneumoniae, MSSA
and MRSA). A two-tailed p-value less than 0.05 was
considered statistically significant. The statistical soft-
ware STATA version 14 (STATACorp LP, College Sta-
tion, TX 77845, USA) was used to perform all
statistical computations.
Results
Selection of the studies
The search of the three electronic databases found 2364
records (Fig. 1). After the removal of duplicates, 999 ci-
tations were screened and only 14 were considered suit-
able for a qualitative and quantitative analysis.
Characteristics of the selected studies
Six [9–14] (42.9%) studies were clinical trials, published
in the time period 2010–2015, and 7 [15–21] (50.0%)
were observational retrospective studies (6, 85.7%, co-
hort studies and 1, 14.3%, case-control study), published
between 2014 and 2016 (Table 1). Only one [22] (7.1%)
study was a retrospective analysis of previous clinical tri-
als. In the majority of the cases (13/14, 92.9%), studies
were carried out from 2007 to 2014 in USA; only the
clinical trial of Zhong et al. [14] was conducted in five
Asian countries. The efficacy/effectiveness of the
Fig. 1 Flow-chart of the systematic review
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Table 1 Summary of the selected studies
First Author Title Publication year Type of study Country Study period
Jandourek et al. [9] Efficacy of ceftaroline fosamil
for bacteremia associated
with community-acquired
bacterial pneumonia
2014 Clinical Trial USA Jul 2007-Dec 2008
File et al. [10] FOCUS 1: a randomized,
double-blinded, multicentre,
Phase III trial of the efficacy
and safety of ceftaroline fosamil
versus ceftriaxone in
community-acquired pneumonia
2011 Clinical Trial USA Jan 2008-Dec 2008
Low et al. [11] FOCUS 2: a randomized,
double-blinded, multicentre,
Phase III trial of the efficacy
and safety of ceftaroline fosamil
versus ceftriaxone in
community-acquired pneumonia
2011 Clinical Trial USA Jul 2007-Aug 2008
Shorr et al. [12] Assessment of ceftaroline fosamil
in the treatment of community-acquired
bacterial pneumonia due to
Streptococcus pneumoniae:
insights from two randomized trials
2013 Clinical Trial USA Jul 2007-Dec 2008
File et al. [13] Integrated analysis of FOCUS
1 and FOCUS 2: randomized,
doubled-blinded, multicenter
phase 3 trials of the efficacy
and safety of ceftaroline fosamil
versus. Ceftriaxone in patients
with community-acquired pneumonia
2010 Clinical Trial USA Jul 2007-Dec 2008
Zhong et al. [14] Ceftaroline fosamil versus
ceftriaxone for the treatment
of Asian patients with
community-acquired pneumonia:
a randomised, controlled,
double-blind, phase 3,
non-inferiority with
nested superiority trial
2015 Clinical Trial China, India, South
Korea, Taiwan, Vietnam
Dec 2011-Apr 2013
Arshad et al. [15] Ceftaroline fosamil for
treatment of Methicillin-Resistant
Staphylococcus aureus
hospital-acquired pneumonia
and health care-associated
pneumonia. A 5-year
matched case-control
evaluation of epidemiology
and outcomes
2016 Case-control study USA Jan 2009-May 2013
Eckburg et al. [22] Day 4 Clinical response
of ceftaroline fosamil
versus ceftriaxone for
community-acquired
bacterial pneumonia
2012 Retrospective integrated
analysis of FOCUS trials
USA Jul 2007-Dec 2008
Guervil et al. [16] Ceftaroline fosamil as
first-line versus second-line
treatment for acute bacterial
skin and skin structure
infections (ABSSSI) or
community-acquired
bacterial pneumonia (CABP)
2015 Retrospective Cohort study USA Aug 2011-Feb 2013
Udeani et al... [17] Ceftaroline fosamil for the
treatment of community-acquired
bacterial pneumonia in elderly patients
2014 Retrospective Cohort study USA Aug 2011-Ap 2013
Ramani et al..... [18] Contemporary use of ceftaroline
fosamil for the treatment
of community-acquired bacterial
pneumonia: CAPTURE study experienc
2014 Retrospective Cohort study USA Aug 2011-Feb 2013
Vasquez et al... [19] Ceftaroline Fosamil for the Treatment
of Staphylococcus aureus Bacteremia
Secondary to Acute Bacterial Skin
and Skin Structure Infections or
Community-Acquired Bacterial Pneumonia
2015 Retrospective Cohort study USA Aug 2011-Feb 2013
Sotgiu et al. Respiratory Research          (2018) 19:205 Page 4 of 13
ceftaroline fosamil arm was compared with that of a
control group in 8 (57.1%) studies [9–15, 22]; in the
remaining 6 studies [16–21] no comparators were
chosen. The dosage of ceftaroline fosamil was the
same across all 14 studies [9–22] (i.e., 600 mg every
12 h). The ceftriaxone was the most frequently (7/8,
87.5%) prescribed antibiotic in controlled studies
(Additional file 1: Table S1).
Characteristics of the enrolled cohort compared with a
control group
The sample size of the studies with a control arm
ranged from 45 to 1153 patients; in particular, the
ceftaroline fosamil arm ranged from 23 to 580 pa-
tients, whereas the control arm sized from 22 to
573 (Table 2). The mean (SD) age of the ceftaroline
and the control group was ~ 60 (15) years, ranging
from 58.8 (16.1) to 66.1 (14.7) years and from 58.8
(16.4) to 65.8 (13.9) years, respectively. The propor-
tion of males was higher than 60%, both in the cef-
taroline and in the control arm, in all studies, with
the only exception of that of Arshad et al. [15],
where the percentage of males was ~ 50% in both
treatment groups. Three (37.5%) studies [9, 12, 22]
did not describe the ethnic origin of the cohort; 3
studies [10, 11, 15] showed a highest (> 80%) preva-
lence of white patients in both arms, whereas the
studies of Zhong et al. [14] and Arshad et al. [15]
had a high proportion of Asian and black patients,
respectively.
The PSI was heterogeneous (Table 3); the majority of
the patients were diagnosed as risk class III or IV. Only
the study of Arshad et al. [15] did not provide a pneu-
monia severity classification. Half of the patients in the
ceftaroline fosamil and control arm were diagnosed as
PSI risk class III. However, the study of Jandourek et al.
[9] recruited two third of the patients diagnosed as PSI
risk class IV. A description of a multi-lobar infiltration,
as well as of a pleural effusion, was performed by two
(25.0%) studies [9, 12]. At least one chronic parenchymal
or airway disease (including COPD, bronchiectasis, and
interstitial fibrosis) affected a proportion of patients ran-
ging from 20.0 to 33.2% per single arm. Asthma was de-
scribed only by four (50.0%) studies [10, 11, 13, 14] and
was found in less than 10% of the patients. Previous epi-
sodes of pneumonia were recorded in one fifth of the
treatment group; however, this information was provided
only by three (37.5%) studies [10, 11, 13]. Four (50.0%)
studies [10–12, 22] found that 1/3–1/2 of the cohort
was previously treated with antibiotics. The prevalence
Table 2 Demographics by treatment groups
Study Sample
size, n
Sample size, n Mean (SD) age, y Male, n (%) Ethnic origina, n (%)
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Jandourek et al....,
2014 [9]
45 23 22 60.6 (16.1) 63.2 (16.2) 15 (65.2) 17 (77.3) – –
File et al.., 2011 [10] 591 291 300 61.0 (16.6) 61.2 (16.4) 187 (64.3) 191 (63.7) 260 (89.3) 268 (83.3)
Low et al, 2011 [11] 562 289 273 60.6 (16.1) 62.0 (14.7) 175 (60.6) 175 (64.1) 278 (96.2) 264 (96.7)
Shorr et al..., 2013
[12]
139 69 70 63 (17) 62 (15) 43 (62.3) 47 (67.1) – –
File et al., 2010 [13] 1153 580 573 60.8 (16.4) 61.6 (15.6) 362 (62.4) 366 (63.9) 538 (92.8) 532 (92.8)
Zhong et al, 2015
[14]
763 381 382 66.1 (14.7) 65.8 (13.9) 265 (69.6) 272 (71.2) 381 (100.0) A 382 (100.0)
A
Arshad et al...., 2016
[15]
149 40 109 58.8 (16.1) 58.8 (16.4) 20 (50.0) 54 (49.5) 16 (40.0) B 46 (42.2) B
Eckburg et al.., 2012
[22]
309 154 155 59.9 (17.7) 60.5 (16.0) 99 (64.3) 97 (62.6) – –
aProportion of white patients, unless otherwise specified as black (B), or Asian (A)
Table 1 Summary of the selected studies (Continued)
First Author Title Publication year Type of study Country Study period
Casapao et al... [20] Large retrospective study
evaluation of the effectiveness
and safety of Ceftaroline
fosamil therapy
2014 Retrospective
observational study
USA Jan 2011-Jun 2013
Kaye et al. [21] Ceftaroline fosamil for
the treatment of hospital
acquired pneumonia and
ventilator associated pneumonia
2015 Retrospective
Cohort study
USA Sep 2013-Mar 2014
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of bacteremia was very low (< 10%) per single arm in 4
(50.0%) studies [10, 11, 13, 14]. Only the study of Jan-
dourek et al. [9] found a bacteremia prevalence of 100%.
Characteristics of the enrolled cohort without a control
group
Six [16–21] out fourteen (42.9%) studies evaluated the
efficacy/effectiveness of ceftaroline fosamil without a
control arm. The sample size was heterogeneous, from
21 to 528 patients (Table 4). The mean (SD) age was
high, ranging from 60 (18) to 64.3 (1.7) years. The pro-
portion of males ranged from 48.3 to 57.5%.
Table 3 Clinical baseline characteristics by treatment groups
Study Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
Ceftaroline
group
Control
group
PSI risk class III, n (%) PSI risk class IV, n (%) Severe CAPa, n (%) Multilobar infiltrate, n (%) Pleural effusion, n (%)
Jandourek et al.., 2014 [9] 5 (21.7) 5 (22.7) 18 (78.3) 15 (68.2) – – 5 (21.7) 5 (22.7) 5 (21.7) 5 (22.7)
File et al........, 2011 [10] 190 (65.3) 182 (60.7) 101 (34.7) 118 (39.3) 82 (28.2) 89 (29.7) – – – –
Low et al...., 2011 [11] 170 (58.8) 171 (62.6) 119 (41.2) 102 (37.4) 99 (34.3) 80 (29.3) – – – –
Shorr et al.........., 2013 [12] 34 (49.3) 37 (52.9) 35 (50.7) 33 (47.1) 22 (31.9) 32 (45.7) 18 (26.1) 21 (30.0) 15 (21.7) 13 (18.6)
File et al, 2010 [13] 360 (62.1) 353 (61.6) 220 (37.9) 220 (38.4) – – – – – –
Zhong et al.., 2015 [14] 255 (67.0) 265(69.4) 126 (33.1) 117 (30.6) – – – – – –
Arshad et al, 2016 [15] – – – – – – – – – –
Eckburg et al, 2012 [22] 84 (54.5) 82 (52.9) 61 (39.6) 61 (39.4) – – – – – –
Structural lung diseaseb,
n (%)
Prior pneumonia,
n (%)
Asthma, n (%) Prior antimicrobial therapy,
n (%)
Bacteremia, n (%)
Jandourek et al, 2014 [9] – – – – – – – – 23 (100.0) 22 (100.0)
File et al, 2011 [10] 64 (22.0) 60 (20.0) 61 (21.0) 51 (17.0) 25 (8.6) 25 (8.3) 137 (47.1) 143 (47.7) 8 (2.7) 9 (3.0)
Low et al, 2011 [11] 96 (33.2) 87 (31.9) 62 (21.5) 41 (15.0) 24 (8.3) 13 (4.8) 100 (34.6) 117 (42.9) 15 (5.2) 11 (4.0)
Shorr et al, 2013 [12] – – – – – – 26 (37.7) 32 (45.7) 19 (27.5) 13 (18.6)
File et al, 2010 [13] 160 (27.6) 147 (25.7) 123 (21.2) 92 (16.1) 49 (8.4) 38 (6.6) – – 23 (4.0) 20 (3.5)
Zhong et al, 2015 [14] 120 (31.5)c 121 (31.7)c – – 21 (5.5) 22 (5.8) 80 (21.0) 85 (22.3) 3 (0.8) 5 (1.3)
Arshad et al, 2016 [15] 8 (20.0) 31 (28.4) – – – – 4 (11.8) 24 (23.3) – –
Eckburg et al, 2012 [22] 43 (27.9) 41 (26.5) – – – – 57 (37.0) 68 (43.9) 23 (14.9) 21 (13.5)
Diabetes mellitus, n (%)
Jandourek et al, 2014 – –
File et al, 2011 – –
Low et al, 2011 – –
Shorr et al, 2013 – –
File et al, 2010 – –
Zhong et al, 2015 62 (16.3) 62 (16.3)
Arshad et al., 2016 10 (25.0) 20 (18.4)
Eckburg et al..., 2012 – –
aModified ATS severe CAP criteria include the presence of three or more of the following at baseline: respiratory rate ≥ 30 breaths/min; O2,90% or PaO2,60 mmHg;
multilobar infiltrates; confusion/disorientation; blood urea nitrogen level ≥ 20 mg/dL; leucopenia (WBC count,4000 cells/mm3); thrombocytopenia (platelet
count,100,000 cells/mm3); hypothermia (core temperature,368C); systolic blood pressure,90 mmHg; or diastolic blood pressure ≤ 60 mmHg. (Niederman MS,
Mandell LA, Anzuetto A et al............ Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial
therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54)
bDefined as any chronic parenchymal or airway disease [e.g. chronic obstructive pulmonary disease (emphysema, chronic bronchitis), bronchiectasis, or
interstitial fibrosis]
conly COPD and chronic bronchitis
Table 4 Demographic characteristics of subjects treated with
only ceftaroline
Study Sample size, n Mean (SD) age, y Male, n (%)
Guervil et al..., 2015 [16] 396 64.3 (1.7) 198 (50.0)
Udeani et al.., 2014 [17] 528 63.6 (20.2) 255 (48.3)
Ramani et al, 2014 [18] 398 63.5 (17.8) 199 (50.0)
Vasquez et al., 2015 [19] 21 60 (18) 11 (52.4)
Casapao et al.., 2014 [20] 92 – –
Kaye et al, 2015 [21] 40 61.3 (16.8) 23 (57.5)
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The prevalence of patients with chronic parenchy-
mal or airway diseases was significantly higher if
compared with that found in the cohort of patients
recruited in controlled studies (40.7–47.5%) (Table 5).
Furthermore, in three out four studies (75%) [16–18]
one fifth of those treated with ceftaroline fosamil
suffered of congestive heart failure. However, the
percentage of previous episodes of pneumonia was
similar (range: 24.6–25.4%). Three (50.0%) studies
[16, 18, 19] described previous antimicrobial expos-
ure, which was higher than 82%.
Efficacy and effectiveness of ceftaroline fosamil
The overall efficacy/effectiveness of ceftaroline fosamil
in all types of pneumonia (i.e., CAP, VAP, HCAP, HAP)
cases was 81.2% (95% CI: 79.9–82.6; I2: 1.2%) (Fig. 2).
The pooled treatment success rate was equal to 81.3%
(95% CI: 80.0–82.7; I2: 7.7%) in patients with CAP, re-
cruited in 12 (85.7%) studies (Fig. 3); a similar pooled
clinical success (83.0%, 95% CI: 65.0–95.0; I2: -) was
found for patients with VAP, HCAP, and HAP, enrolled
in 2 (14.3%) studies (Fig. 4).
In the 8 (57.1%) controlled studies [9–15, 22] the
pooled relative risk of clinical cure was 1.1 (95% CI: 1.1–
1.2; I2: 0.0%) (Fig. 5).
The stratified analysis according to the microbiological
diagnosis showed a high clinical and microbiological suc-
cess: it was 82.6% (95% CI: 78.6–86.4; I2: 0.0%) in patients
with a lung infection caused by S. pneumoniae, 93.0%
(95% CI: 77.0–100.0; I2: 0.0%) in those with a MDR S.
pneumoniae infection (Figs. 6 and 7). The cases of pneu-
monia caused by MSSA and MRSA showed a pooled suc-
cess rate of 72.3% (95% CI: 64.5–79.4; I2: 0.0%) and 71.7%
(95% CI: 59.7–82.3; I2: 67.9%), respectively (Figs. 8 and 9).
Table 5 Clinical characteristics of subjects treated with only ceftaroline
Study Structural lung
diseasea, n (%)
Congestive
heart failure, n (%)
Prior pneumonia, n (%) GERD, n (%) Smoking, n (%) Prior antimicrobial
therapy, n (%)
Guervil et al, 2015 [16] 161 (40.7) 79 (20.0) 98 (24.8) 91 (23.0) 114 (28.8) 396 (100.0)
Udeani et al....., 2014 [17] 228 (43.2) 113 (21.4) 134 (25.4) 127 (24.1) 159 (30.1) –
Ramani et al.., 2014 [18] 162 (40.7) 80 (20.1) 98 (24.6) 92 (23.1) 114 (28.6) 328 (82.4)
Vasquez et al..., 2015 [19] – – – – – 18 (85.7)
Casapao et al......, 2014 [20] – – – – – –
Kaye et al., 2015 [21] 19 (47.5) 8 (0.20) 10 (25.0) 10 (25.0) 21 (52.5) –
aDefined as any chronic parenchymal or airway disease [e.g. chronic obstructive pulmonary disease (emphysema, chronic bronchitis), bronchiectasis, or
interstitial fibrosis]
Fig. 2 Efficacy of ceftaroline in the overall pneumonia (including CAP, VAP, HCAP, HAP)
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Safety and tolerability of ceftaroline fosamil
Only 4 (28.6%) studies [10, 11, 13, 14] described the
safety profile of the ceftaroline fosamil and control
group: the percentage of adverse events ranged from
39.9 to 53.7% in the ceftaroline fosamil arm, whereas it
ranged from 42.7 to 47.2% in the control arm (Table 6).
The most frequently reported adverse events were: diar-
rhea, headache, insomnia, nausea, phlebitis, hyperten-
sion, and hypokalemia; however, their point prevalence
was less than 5% in the ceftaroline fosamil group.
Mortality rate in ceftaroline-treated arm is summarized
in the Table 7.
Discussion
This systematic review and meta-analysis confirms the
positive results on ceftaroline fosamil described in
single observational and experimental studies. It pools
observational findings from a real-world scenario as
well as experimental results from the clinical trial
world. The final message highlights the high efficacy
Fig. 3 Clinical success in CAP subjects treated with ceftaroline
Fig. 4 Clinical success in HAP/VAP/HCAP subjects treated with ceftaroline
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and effectiveness of ceftaroline fosamil in patients
with different types of pneumonia, including CAP,
HAP, VAP and HCAP, as well as its good safety and
tolerability profile.
All the selected studies found a high pooled clinical
success rate (> 80%) across all types of pneumonia, dem-
onstrating poor variability between studies and between
pneumonia types. However, the majority of the selected
studies focused the attention on CAP and only two stud-
ies on pneumonias other than CAP [15, 21].
One of the most important findings is the high micro-
biological cure against drug-susceptible and –resistant S.
pneumoniae strains. In the last two decades, it has
been described the emergence and spread of MDR
isolates, as well as the decreased vaccination coverage
and the replacement of vaccine-related with other
non-vaccine-related serotypes. The possibility of in-
creasing the current antibiotic armamentarium with
new effective and safe drugs can improve the progno-
sis of some patients.
More attention needs to be deserved to the MSSA
and MRSA. The current therapeutic options (e.g.,
glycopeptides or linezolid) could be inappropriate or
not available in some geographical settings. The high
frequency of MRSA both in the hospital and in the
community should be carefully monitored and ad-
equate therapeutic options are necessary. Ceftaroline
fosamil has demonstrated a high clinical cure rate
(> 70%) in forms of pneumonia caused by MSSA and
MRSA strains.
The broad-spectrum activity of ceftaroline fosamil
against gram-positive and –negative bacteria could rep-
resent an added value in case of complicated polymicro-
bial infections, as well as in case of empirical therapy
when the collection of respiratory specimens is negative
or not feasible.
Several limitations of the present study can be de-
tected: only experimental studies with positive and sig-
nificant results on ceftaroline fosamil could have been
published, representing a publication bias. Nevertheless,
Fig. 5 Effect of ceftaroline on clinical cure
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the confirmation of the experimental findings with ob-
servational and real-life results supports the reliability of
the clinical and microbiological findings. The selection
of non-controlled studies could reduce the statistical
power of some findings and represent a methodological
limitation; however, the necessity of recruiting real-life
studies and the homogeneity of the results on the effi-
cacy across the studies provide robustness to the
inferential analysis. The geographical representation is
partially jeopardized, with a highest prevalence of studies
carried out in the USA. This could reduce the
generalizability of the findings to some geographical
areas (e.g., Africa, Europe), which could show differences
in terms of microbial ecology (antibiotic resistance rates
and different microbial burden) and of patients’ charac-
teristics. Yet, the scientific evidence provided by high-,
Fig. 7 Clinical cure rates in subjects with MDR Streptococcus pneumoniae treated with ceftaroline at TOC visit
Fig. 6 Clinical and microbiological response rates in subjects with Streptococcus pneumoniae treated with ceftaroline
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middle-, and low-income (Asian countries) settings
could reduce this selection bias, as demonstrated by Ali-
berti et al. [4].
It was proved a clear confirmation of the efficacy and
effectiveness of ceftaroline fosamil in patients with CAP
but only a few studies (i.e., two) assessed its role in other
pneumonia entities (e.g., HCAP), which can be caused
by MDR bacteria in difficult-to-treat patients with severe
clinical conditions and comorbidities. One of the main
shortcomings of the published studies is the limited
focus on the antibiotic safety. An individual patient data
meta-analysis, with the involvement of all the authors of
the published studies, could better analyze this critical
point.
No studies have evaluated pharmacological interac-
tions in randomized clinical trials with other antibiotics
Fig. 8 Clinical and microbiological response rates in subjects with MSSA treated with ceftaroline
Fig. 9 Clinical and microbiological response rates in subjects with MRSA treated with ceftaroline
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or drugs prescribed for chronic diseases. Further-
more, evidence should be provided for some at-risk
patient categories, such as children, pregnant and
breast-feeding women, elderly people. This systematic
review selected clinical studies where a high propor-
tion of patients with comorbidities was enrolled.
However, more significant findings are needed, along
with specific studies on the efficacy against other less
incident bacterial pathogens.
In conclusion, this study provides a systematic col-
lection and critical analysis of the present scientific
evidence on ceftaroline fosamil. A few years after its
distribution in the market, it has been shown its high
efficacy and effectiveness, as well as its safety and tol-
erability. However, its effectiveness can be preserved
in the near future if prescribed appropriately
following antimicrobial stewardship policies and
proved in vitro drug susceptibility in individual cases.
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